Rhumbline Advisers Reduces Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

Rhumbline Advisers reduced its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,052 shares of the company’s stock after selling 2,275 shares during the quarter. Rhumbline Advisers’ holdings in Fresenius Medical Care were worth $363,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in FMS. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care during the 3rd quarter valued at about $38,000. Venturi Wealth Management LLC raised its stake in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after buying an additional 4,800 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Fresenius Medical Care by 43.3% in the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after buying an additional 2,166 shares during the period. Franklin Street Advisors Inc. NC bought a new stake in Fresenius Medical Care during the 4th quarter valued at approximately $201,000. Finally, Autumn Glory Partners LLC bought a new stake in Fresenius Medical Care during the 4th quarter valued at approximately $208,000. 8.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

FMS has been the subject of several research reports. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial increased their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd.

Fresenius Medical Care Price Performance

FMS stock opened at $23.98 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a 50 day moving average price of $23.53 and a 200-day moving average price of $22.05. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25. The firm has a market capitalization of $14.07 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 0.76 and a beta of 0.99.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.